TREATMENT OF HBEAG-POSITIVE CHB INFECTION WITH PEGINTERFERON ALFA-2A [40KD] PLUS LAMIVUDINE OR ADEFOVIR FOR 96 WEEKS RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION

被引：0

作者：

Cao, Zhenhuan ^{[1
]}

Zhang, Yonghong ^{[1
]}

Ma, Lina ^{[1
]}

Jin, Yi ^{[1
]}

Yu, Haibin ^{[1
]}

Zhang, Xiao-dan ^{[1
]}

Liu, Yali ^{[1
]}

Huang, Yanxiang ^{[1
]}

Ma, Bing ^{[1
]}

Ren, Shan ^{[1
]}

Wang, Lilin ^{[1
]}

Chen, Xin-Yue ^{[1
]}

Wei, Lai ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

来源：

HEPATOLOGY | 2010年 / 52卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

377

引用

页码：507A / 507A

页数：1

共 50 条

[1] PEGINTERFERON ALFA-2A [40KD] PLUS ADEFOVIR FOR 96 WEEKS IN HBEAG-NEGATIVE CHB RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION
Cao, Z.
Yu, H.
Ma, L.
Zhang, Y.
Liu, Y.
Ma, B.
Wu, H.
Chen, X.
JOURNAL OF HEPATOLOGY, 2011, 54 : S283 - S283
[2] ON-TREATMENT HBSAG DECLINE DURING PEGINTERFERON ALFA-2A (40KD) ± LAMIVUDINE IN PATIENTS WITH HBEAG-POSITIVE CHB AS A POTENTIAL PREDICTOR OF DURABLE OFF-TREATMENT RESPONSE
Lau, George K.
Marcellin, Patrick
Brunetto, Maurizia
Piratvisuth, Teerha
Kapprell, Hans-Peter
Button, Peter
Batrla, Richard
HEPATOLOGY, 2008, 48 (04) : 714A - 714A
[3] Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion
Cao, Zhen Huan
Ma, Li Na
Zhang, Hong Wei
Liu, Ya Li
Chen, Xin Yue
JOURNAL OF DIGESTIVE DISEASES, 2013, 14 (08) : 446 - 450
[4] HBeAg and HBV DNA kinetics in HBsAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)
Fried, M. W.
Liaw, Y. F.
Luo, K. X.
Lau, G. K. K.
Piratvisuth, T.
Cooksley, G.
Marcellin, P.
Flisiak, R.
Popescu, M.
Button, P.
JOURNAL OF HEPATOLOGY, 2006, 44 : S183 - S183
[5] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
Caruntu, Florin Alexandru
Streinu-Cercel, Adrian
Gheorghe, Liliana Simona
Grigorescu, Mircea
Sporea, Ioan
Stanciu, Carol
Andronescu, Dan
Voinea, Florea
Diculescu, Mircea
Oproiu, Alexandru
Voiosu, Rodu
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
[6] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
Piratvisuth, T
Marcellin, P
Lau, G
Bonino, F
Farci, P
Hadziyannis, S
Jin, R
Lu, ZM
Germanidis, G
Yurdaydin, C
Diago, M
Gurel, S
Lai, MY
Button, P
Why, RD
Pluck, N
HEPATOLOGY, 2004, 40 (04) : 656A - 657A
[7] HBV DNA suppression induced by peginterferon alfa-2a (40kd) but not by lamivudine results in HBsAg loss and seroconversion at 3 years post-treatment
Brunetto, M.
Bonino, E.
Marcellin, P.
Lau, G. K. K.
Farci, P.
Yurdaydin, C.
Piratvisuth, T.
Hadziyannis, S.
Lu, Z. -M.
Wu, J.
Popescu, M.
JOURNAL OF HEPATOLOGY, 2008, 48 : S254 - S254
[8] Characterization of Hepatitis B Surface Proteins in HBeAg-positive Patients with Chronic Hepatitis B (CHB) Treated With PegInterferon Alfa-2a (40KD)
Rinker, Franziska
Bremer, Corinna M.
Wiegand, Steffen B.
Bremer, Birgit
Manns, Michael P.
Wedemeyer, Heiner
Yang, Lei
Pavlovic, Vedran
Wat, Cynthia
Glebe, Dieter
Kraft, Anke R.
Cornberg, Markus
HEPATOLOGY, 2015, 62 : 1196A - 1197A
[9] Enhanced pharmacokinetics (PK) and pharmacodynamics (PD) of peginterferon alfa-2a (40KD) (PEGASYS®) vs conventional interferon alfa-2a in HBeAg-positive chronic hepatitis B (CHB)
Choudhury, S
Wang, YJ
Thongasawat, S
Minde, Z
Chan, WY
Piratvisuth, T
Yuan, R
ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER MEETING 2002, 2002, : 95 - 100
[10] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
Jakubczyk, M.
Paweska, J.
Niewada, M.
Berak, H.
Szkultecka-Debek, M.
Russel-Szymczyk, M.
VALUE IN HEALTH, 2011, 14 (07) : A275 - A275

← 1 2 3 4 5 →